Mitochon Pharmaceuticals
Radnor
About Mitochon Pharmaceuticals
Mitochon Pharmaceuticals is a start-up biotech company, formed in 2014, that focuses on developing drugs that target the mitochondria for a host of serious diseases with significant unmet medical needs. Their development programs are primarily focused on neurodegenerative & neuromuscular diseases including: Huntington’s, Batten Disease, Stroke, Duchenne Muscular Dystrophy (DMD), Alzheimer’s Disease, Parkinson Disease and severe burns, and secondarily on metabolic disorders due to over-nutrition (diabetes, obesity and NASH). On-going research has linked these diseases to various malfunctions of the mitochondria. By correcting them, Mitochon aims at opening the way for a broad range of disease modifying therapies. Mitochon is led by a team of industry executives with over 80-years of combined experience and a passion to bring forward breakthrough drug therapies for a host of devastating diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $2.3M
- Last round: Series Unknown (May 2016)
- Website: mitochonpharma.com
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/mitochon-pharmaceuticals-146659 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.